A cut on the skin of a young person closes in days. In an older adult, the same wound can linger for weeks. For over a decade, aging researchers pointed to one villain: senescent cells, the so-called “zombie” cells that stop dividing but refuse to die, piling up in tissues and fueling chronic inflammation. The fix seemed obvious. Kill them all.
New research says that logic is dangerously incomplete. A review published in the journal Aging-US in May 2026, synthesizing more than a decade of experimental findings on cellular senescence, argues that senescent cells are far more varied than the field assumed. Some drive disease. Others actively support wound healing, prevent scarring, and even help shape organs before birth. No DOI or named author list has been confirmed for this review at the time of writing, but its central thesis poses an uncomfortable question for the booming senolytic drug industry: if a therapy wipes out every senescent cell in the body, does it also destroy the ones quietly keeping tissues functional?
A separate review published in npj Aging, part of the Nature Portfolio, reaches a similar conclusion. Its authors argue that the field is shifting away from blanket “kill all senescent cells” strategies and toward precision approaches that can distinguish helpful populations from harmful ones. Full author names and institutional affiliations for that paper have not been independently verified.
The cells that heal
The strongest evidence for protective senescence comes from wound repair. In a 2014 study published in Developmental Cell, researchers showed that senescent cells at wound sites secrete a growth factor called PDGF-AA, and that this secretion is essential for timely skin wound closure. When the team disrupted PDGF signaling, healing slowed measurably. The senescent cells were not bystanders. They were running part of the repair program.
A related finding, published in Nature Cell Biology, showed that a protein called CCN1 triggers fibroblast senescence through specific receptor interactions during wound healing. Those senescent fibroblasts then switch on antifibrotic genes. When researchers engineered mice with impaired CCN1-induced senescence, the animals developed significantly worse fibrosis during wound repair. Without the right senescent cells in place, scar tissue ran unchecked.
The protective role is not limited to injury. Research published in the journal Cell demonstrated that senescence occurs on a programmed schedule during mammalian embryonic development, governed by the cell-cycle regulator p21. In developing embryos, senescent cells appear at specific locations, are cleared by the immune system, and are replaced through tissue remodeling. Senescence, in this context, is not a sign of damage. It is a built-in developmental tool.
The cells that destroy
None of this erases the well-established harm. Senescent cells that linger for months or years release a complex mix of inflammatory signals, tissue-degrading enzymes, and growth factors collectively known as the senescence-associated secretory phenotype, or SASP. In the short term, SASP can recruit immune cells and promote repair. Over time, when senescent cells are not cleared, the same signals drive chronic inflammation, tissue breakdown, and age-related diseases including osteoarthritis, atherosclerosis, and pulmonary fibrosis.
A detailed review in Nature Reviews Molecular Cell Biology described SASP as context-dependent: beneficial when transient, destructive when chronic. The difference between a senescent cell that helps and one that harms often comes down to how long it stays and what tissue surrounds it.
This is the core tension the new reviews highlight. The same biological machinery that accelerates wound healing in a 30-year-old can fuel joint degeneration in a 70-year-old. Timing and clearance, not the cells themselves, determine the outcome.
What researchers still cannot do
The biggest obstacle to acting on these findings is measurement. No published study has quantified the ratio of beneficial to harmful senescent cells across different human tissues or age groups. Researchers know the ratio matters, but they lack reliable biomarkers to distinguish protective populations from destructive ones in a living patient. Without that ability, “precision senotherapy” remains a goal, not a product.
Specific drug targets are also unresolved. PDGF-AA and CCN1 have been identified as beneficial signals in wound-healing experiments, but no clinical data yet show whether a therapy can preserve those pathways while eliminating harmful senescent cells nearby. The SASP alone contains dozens of distinct factors. Which ones to block and which to spare in a treatment setting has not been tested in human trials.
Longitudinal evidence adds another layer of uncertainty. Studies in mice have shown that clearing senescent cells can extend healthspan, but no long-term experiment has tracked what happens to wound healing or tissue repair when beneficial senescent populations are selectively preserved in aged animals. The mechanistic evidence from cell culture and genetic mouse models is strong. The translation to human aging is not yet complete.
What this means for senolytic drugs in development
Several senolytic therapies are already in early-stage clinical trials. The combination of dasatinib and quercetin, first shown to clear senescent cells in mice by researchers at the Mayo Clinic, has been tested in small human studies targeting idiopathic pulmonary fibrosis and diabetic kidney disease. Unity Biotechnology has run trials of senolytic eye injections for age-related macular degeneration. Fisetin, a plant flavonoid, is being studied in trials for osteoarthritis and frailty in older adults.
The new reviews do not invalidate these efforts. But they do raise a caution that trial designers and patients should take seriously. Broad-spectrum senolytics that eliminate all senescent cells could impair short-term healing after injury or surgery, precisely the situations where protective senescent cells appear to matter most. For older adults, who heal more slowly to begin with, that tradeoff could be significant.
Anyone considering experimental anti-aging treatments, or even over-the-counter supplements marketed as senolytics, should understand that the science no longer supports a simple “fewer senescent cells equals better health” framework. The question is no longer whether to remove senescent cells. It is which ones, when, and from where.
Why precision senotherapy is still years away from the clinic
The direction is toward specificity. Researchers need biomarkers that can flag harmful senescent cells for removal while leaving protective ones intact. They need tissue-level maps showing where beneficial senescence concentrates, particularly in skin, liver, and lung tissue where repair demands are high. And they need clinical trials designed to measure healing outcomes alongside disease markers, not just senescent cell counts.
That work will take years. In the meantime, the old “zombie cell” label, while catchy, now tells only part of the story. Some of those cells are not lurching toward destruction. They are standing guard.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
